Can I read Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study on EtoBox?

Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study by Chengpei Zhu; Hu Li; Xiaobo Yang; Shanshan Wang; Yunchao Wang; Nan Zhang; Yanyu Wang; Jingnan Xue; Longhao Zhang; Cong Ning; Xu Yang; Ziyu Xun; Jiashuo Chao; Junyu Long; Xinting Sang; Zhenyu Zhu; Haitao Zhao is a Immunology and Microbiology article available to read on EtoBox.

What is Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study about?

## Background A programmed cell death protein-1 (PD-1) inhibitor combined with lenvatinib and Gemox chemotherapy as first-line therapy demonstrated high anti-tumor activity against biliary tract cancer in phase II clinical trials. Herein, we aimed to investigate the efficacy and safety for advanced intrahepatic cholangiocarcinoma (ICC) in a multicenter real-world study. ## Methods Patients with advanced ICC who received PD-1 inhibitor combined with lenvatinib and Gemox chemotherapy were retrospectively screened at two medical centers. The primary endpoints were overall survival (OS) and progression-free survival (PFS), whereas the secondary endpoints were objective response rate (ORR), disease control rate (DCR), and safety. Prognostic factors for survival were analyzed. ## Results Fifty-three patients with advanced ICC were included in this study. The median follow-up time was 13.7 (95% confidence interval (CI): 12.9–17.2) months. The median OS and PFS were 14.3 (95% CI: 11.3–NR) and 8.63 (95% CI: 7.17–11.6) months, respectively. The ORR, DCR, and clinical benefit rate were 52.8, 94.3, and 75.5%, respectively. In the multivariate analysis, the tumor burden score (TBS), tumor-node

Who reads Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study?

Author

Chengpei Zhu; Hu Li; Xiaobo Yang; Shanshan Wang; Yunchao Wang; Nan Zhang; Yanyu Wang; Jingnan Xue; Longhao Zhang; Cong Ning; Xu Yang; Ziyu Xun; Jiashuo Chao; Junyu Long; Xinting Sang; Zhenyu Zhu; Haitao Zhao

Publisher

Springer

Published

2023

Language

EN

Field

Immunology and Microbiology (Life Sciences)